BioWorld: The Daily Biopharmaceutical and Medical Technology …
WEBBig pharma eyes China ‘at forefront of GLP-1 revolution’. Two leading glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes – Novo Nordisk A/S’s semaglutide (Wegovy/Ozempic) and Eli Lilly and Co.’s... More in BioWorld Asia. Daily news and analysis of the global biotechnology, pharmaceutical and medical ...
Getinge to acquire Paragonix for $477M | BioWorld
WEBAug 23, 2024 · Getinge AB agreed to acquire Paragonix Technologies Inc. for $477 million, including upfront and earn out payments. The deal marks Getinge’s entry into the global organ preservation and transportation market, a rapidly advancing field driven by rising transplant volumes, technological innovations and evolving clinical practices.
Focusing on tumor cells brings insights into cancer neuroscience
WEBSep 10, 2024 · By looking at the electrical activity of tumor cells, rather than the neurons that innervate them, investigators at Baylor College of Medicine have added both basic and translational insights to the emerging field of cancer neuroscience. In their studies, which were published in Cancer Cell on Sept. 5, 2024, the researchers identified the cell of origin for IDH-mutated gliomas.
Shanghai Apeiron Biotechnology discloses PRMT5 inhibitors
WEBFeb. 22, 2024. Shanghai Apeiron Biotechnology Co. Ltd. has patented new protein arginine N -methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer. BioWorld Science Cancer Patents. Highfield Biopharmaceuticals files IND in China for immunoliposome HF-50 for solid tumors.
Money raised by biopharma - BioWorld
WEBMoney raised by biopharma. May 31, 2024. Total raised in public, private and other financings of biopharma companies, comparing 2019-2024. BioWorld Analysis and data insight Briefs. Highfield Biopharmaceuticals Inc. has filed an IND application with China’s National Medical Products Administration (NMPA) to conduct a clinical trial of HF-50,...
Precision Biosciences advances PBGENE-HBV toward clinic
WEBFeb. 15, 2024. Precision Biosciences Inc. has received pre-IND regulatory feedback from the FDA and ex-U.S. agencies providing alignment and clarity on Precision's final IND/CTA-enabling preclinical plans and clinical strategy for PBGENE-HBV. BioWorld Science Infection Gene therapy FDA.
High efficacy of SIBP-03 in combination with EGFR and HER2
WEBJan 17, 2024 · High efficacy of SIBP-03 in combination with EGFR and HER2 therapies. Targeting human epidermal growth factor receptor 3 (HER3) has been explored as a strategy for cancer treatment. Highfield Biopharmaceuticals Inc. has filed an IND application with China’s National Medical Products Administration (NMPA) to …
Neuroninn Biosciences divulges new GPR139 agonists | BioWorld
WEBFeb 13, 2024 · Neuroninn Biosciences Co. Ltd. has synthesized G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of anxiety disorders, depression, substance abuse and dependence and Parkinson’s disease. Highfield Biopharmaceuticals Inc. has filed an IND application with China’s National Medical Products Administration (NMPA ...
Metabolexis to develop treatments for obesity and type 2 diabetes
WEBOct. 27, 2023. Biolexis Therapeutics Inc. has reported the launch of Metabolexis, a new pipeline company developing three targeted oral small molecules for the treatment of obesity and type 2 diabetes. BioWorld Science Newco news Endocrine/metabolic. Highfield Biopharmaceuticals Inc. has filed an IND application with China’s National Medical ...
lncMALAT1 behind multiple myeloma and its prognosis
WEBJun 18, 2024 · Angiogenesis plays a crucial role in multiple myeloma and its prognosis, with the success of antiangiogenic therapies being limited. Exosomes mediate cell-to-cell cross talk during the progression of cancer by transporting their molecular cargo, which include long non-coding RNAs (lncRNAs); their role in multiple myeloma was investigated.
Skip to content